# AvePoint, Inc.: financial statements, quarterly

AVPT · Nasdaq · CIK 1777921 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/avpt.md) · [Financials](/companies/avpt/financials.md) · [Filings](/companies/avpt/filings.md) · [Insiders](/companies/avpt/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/avpt/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [72.8](/filings/0001437749-24-033984.md) | [74.6 d](/filings/0001437749-26-005907.md) | [74.5](/filings/0001437749-25-015552.md) | [78.0](/filings/0001437749-25-025492.md) | [88.8](/filings/0001437749-25-033626.md) | [89.2 d](/filings/0001437749-26-005907.md) | [93.1](/filings/0001437749-26-015588.md) | [102](/filings/0001437749-26-026267.md) | [110](/filings/0001437749-25-033626.md) | [115 d](/filings/0001437749-26-005907.md) | [117](/filings/0001437749-26-015588.md) | [124](/filings/0001437749-26-026267.md) |
| Cost of revenue | $m | [20.2](/filings/0001437749-24-033984.md) | [19.6 d](/filings/0001437749-26-005907.md) | [20.4](/filings/0001437749-25-015552.md) | [18.9](/filings/0001437749-25-025492.md) | [21.2](/filings/0001437749-25-033626.md) | [21.9 d](/filings/0001437749-26-005907.md) | [23.9](/filings/0001437749-26-015588.md) | [26.5](/filings/0001437749-26-026267.md) | [28.1](/filings/0001437749-25-033626.md) | [30.3 d](/filings/0001437749-26-005907.md) | [31.9](/filings/0001437749-26-015588.md) | [33.5](/filings/0001437749-26-026267.md) |
| Gross profit | $m | [52.6](/filings/0001437749-24-033984.md) | [55.0 d](/filings/0001437749-26-005907.md) | [54.1](/filings/0001437749-25-015552.md) | [59.0](/filings/0001437749-25-025492.md) | [67.6](/filings/0001437749-25-033626.md) | [67.3 d](/filings/0001437749-26-005907.md) | [69.2](/filings/0001437749-26-015588.md) | [75.5](/filings/0001437749-26-026267.md) | [81.6](/filings/0001437749-25-033626.md) | [84.4 d](/filings/0001437749-26-005907.md) | [85.4](/filings/0001437749-26-015588.md) | [91.0](/filings/0001437749-26-026267.md) |
| Research and development | $m | [8.6](/filings/0001437749-24-033984.md) | [9.4 d](/filings/0001437749-26-005907.md) | [10.5](/filings/0001437749-25-015552.md) | [12.5](/filings/0001437749-25-025492.md) | [12.8](/filings/0001437749-25-033626.md) | [12.9 d](/filings/0001437749-26-005907.md) | [12.7](/filings/0001437749-26-015588.md) | [13.0](/filings/0001437749-26-026267.md) | [13.9](/filings/0001437749-25-033626.md) | [13.0 d](/filings/0001437749-26-005907.md) | [13.8](/filings/0001437749-26-015588.md) | [16.6](/filings/0001437749-26-026267.md) |
| Selling, general and administrative | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(0.3)](/filings/0001437749-24-033984.md) | [0.9 d](/filings/0001437749-26-005907.md) | [(3.2)](/filings/0001437749-25-015552.md) | [(2.1)](/filings/0001437749-25-025492.md) | [7.7](/filings/0001437749-25-033626.md) | [4.9 d](/filings/0001437749-26-005907.md) | [3.3](/filings/0001437749-26-015588.md) | [7.1](/filings/0001437749-26-026267.md) | [8.1](/filings/0001437749-25-033626.md) | [14.5 d](/filings/0001437749-26-005907.md) | [12.7](/filings/0001437749-26-015588.md) | [10.2](/filings/0001437749-26-026267.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [2.8](/filings/0001437749-24-033984.md) | [(5.2) d](/filings/0001437749-26-005907.md) | [2.2](/filings/0001437749-25-015552.md) | [3.8](/filings/0001437749-25-025492.md) | [0.2](/filings/0001437749-25-033626.md) | [(1.4) d](/filings/0001437749-26-005907.md) | [1.3](/filings/0001437749-26-015588.md) | [4.0](/filings/0001437749-26-026267.md) | [(0.2)](/filings/0001437749-25-033626.md) | [0.3 d](/filings/0001437749-26-005907.md) | [1.3](/filings/0001437749-26-015588.md) | [(15.6)](/filings/0001437749-26-026267.md) |
| Net income | $m | [(4.2)](/filings/0001437749-23-031307.md) | [4.3 d](/filings/0001437749-26-005907.md) | [(2.0)](/filings/0001437749-25-015552.md) | [(12.9)](/filings/0001437749-25-025492.md) | [2.6](/filings/0001437749-25-033626.md) | [(17.2) d](/filings/0001437749-26-005907.md) | [3.4](/filings/0001437749-26-015588.md) | [2.7](/filings/0001437749-26-026267.md) | [13.0](/filings/0001437749-25-033626.md) | [15.6 d](/filings/0001437749-26-005907.md) | [15.3](/filings/0001437749-26-015588.md) | [27.6](/filings/0001437749-26-026267.md) |
| Diluted EPS | $ per share | [(0.02)](/filings/0001437749-24-033984.md) | not reported | [(0.01)](/filings/0001437749-25-015552.md) | [(0.07)](/filings/0001437749-25-025492.md) | [0.01](/filings/0001437749-25-033626.md) | not reported | [0.02](/filings/0001437749-26-015588.md) | [0.01](/filings/0001437749-26-026267.md) | [0.06](/filings/0001437749-25-033626.md) | not reported | [0.07](/filings/0001437749-26-015588.md) | [0.12](/filings/0001437749-26-026267.md) |
| Basic EPS | $ per share | [(0.02)](/filings/0001437749-24-033984.md) | not reported | [(0.01)](/filings/0001437749-25-015552.md) | [(0.07)](/filings/0001437749-25-025492.md) | [0.01](/filings/0001437749-25-033626.md) | not reported | [0.02](/filings/0001437749-26-015588.md) | [0.01](/filings/0001437749-26-026267.md) | [0.06](/filings/0001437749-25-033626.md) | not reported | [0.07](/filings/0001437749-26-015588.md) | [0.13](/filings/0001437749-26-026267.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss, us-gaap:ProfitLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [206](/filings/0001437749-23-031307.md) | [223](/filings/0001437749-25-005526.md) | [215](/filings/0001437749-24-015724.md) | [227](/filings/0001437749-24-025596.md) | [250](/filings/0001437749-24-033984.md) | [291](/filings/0001437749-26-005907.md) | [351](/filings/0001437749-25-015552.md) | [430](/filings/0001437749-25-025492.md) | [472](/filings/0001437749-25-033626.md) | [481](/filings/0001437749-26-026267.md) | [444](/filings/0001437749-26-015588.md) | [417](/filings/0001437749-26-026267.md) |
| Current assets | $m | [287](/filings/0001437749-23-031307.md) | [326](/filings/0001437749-25-005526.md) | [304](/filings/0001437749-24-015724.md) | [317](/filings/0001437749-24-025596.md) | [341](/filings/0001437749-24-033984.md) | [395](/filings/0001437749-26-005907.md) | [447](/filings/0001437749-25-015552.md) | [540](/filings/0001437749-25-025492.md) | [581](/filings/0001437749-25-033626.md) | [625](/filings/0001437749-26-026267.md) | [562](/filings/0001437749-26-015588.md) | [557](/filings/0001437749-26-026267.md) |
| Total assets | $m | [398](/filings/0001437749-23-031307.md) | [443](/filings/0001437749-25-005526.md) | [414](/filings/0001437749-24-015724.md) | [427](/filings/0001437749-24-025596.md) | [463](/filings/0001437749-24-033984.md) | [519](/filings/0001437749-26-005907.md) | [599](/filings/0001437749-25-015552.md) | [700](/filings/0001437749-25-025492.md) | [744](/filings/0001437749-25-033626.md) | [789](/filings/0001437749-26-026267.md) | [734](/filings/0001437749-26-015588.md) | [757](/filings/0001437749-26-026267.md) |
| Current liabilities | $m | [149](/filings/0001437749-23-031307.md) | [177](/filings/0001437749-25-005526.md) | [163](/filings/0001437749-24-015724.md) | [173](/filings/0001437749-24-025596.md) | [195](/filings/0001437749-24-033984.md) | [223](/filings/0001437749-26-005907.md) | [208](/filings/0001437749-25-015552.md) | [228](/filings/0001437749-25-025492.md) | [245](/filings/0001437749-25-033626.md) | [274](/filings/0001437749-26-026267.md) | [260](/filings/0001437749-26-015588.md) | [279](/filings/0001437749-26-026267.md) |
| Total liabilities | $m | [184](/filings/0001437749-23-031307.md) | [218](/filings/0001437749-25-005526.md) | [201](/filings/0001437749-24-015724.md) | [220](/filings/0001437749-24-025596.md) | [247](/filings/0001437749-24-033984.md) | [248](/filings/0001437749-26-005907.md) | [237](/filings/0001437749-25-015552.md) | [257](/filings/0001437749-25-025492.md) | [277](/filings/0001437749-25-033626.md) | [310](/filings/0001437749-26-026267.md) | [295](/filings/0001437749-26-015588.md) | [320](/filings/0001437749-26-026267.md) |
| Shareholders' equity | $m | [200](/filings/0001437749-23-031307.md) | [219](/filings/0001437749-24-015724.md) | [213](/filings/0001437749-24-015724.md) | [207](/filings/0001437749-25-033626.md) | [216](/filings/0001437749-25-033626.md) | [271](/filings/0001437749-26-026267.md) | [361](/filings/0001437749-26-026267.md) | [443](/filings/0001437749-26-026267.md) | [467](/filings/0001437749-25-033626.md) | [479](/filings/0001437749-26-026267.md) | [439](/filings/0001437749-26-026267.md) | [437](/filings/0001437749-26-026267.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity, us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [4.0 d](/filings/0001437749-24-033984.md) | [21.4 d](/filings/0001437749-26-005907.md) | [7.8](/filings/0001437749-25-015552.md) | [16.2 d](/filings/0001437749-25-025492.md) | [32.2 d](/filings/0001437749-25-033626.md) | [32.8 d](/filings/0001437749-26-005907.md) | [0.5](/filings/0001437749-26-015588.md) | [20.3 d](/filings/0001437749-26-026267.md) | [34.8 d](/filings/0001437749-25-033626.md) | [29.7 d](/filings/0001437749-26-005907.md) | [24.3](/filings/0001437749-26-015588.md) | [15.9 d](/filings/0001437749-26-026267.md) |
| Capital expenditure | $m | [0.7 d](/filings/0001437749-24-033984.md) | [0.6 d](/filings/0001437749-26-005907.md) | [0.5](/filings/0001437749-25-015552.md) | [0.4 d](/filings/0001437749-25-025492.md) | [1.4 d](/filings/0001437749-25-033626.md) | [0.7 d](/filings/0001437749-26-005907.md) | [1.5](/filings/0001437749-26-015588.md) | [1.0 d](/filings/0001437749-26-026267.md) | [0.5 d](/filings/0001437749-25-033626.md) | [0.7 d](/filings/0001437749-26-005907.md) | [1.3](/filings/0001437749-26-015588.md) | [1.2 d](/filings/0001437749-26-026267.md) |
| Share repurchases | $m | [16.6 d](/filings/0001437749-24-033984.md) | [5.4 d](/filings/0001437749-26-005907.md) | [13.7](/filings/0001437749-25-015552.md) | [5.4 d](/filings/0001437749-25-025492.md) | [2.6 d](/filings/0001437749-25-033626.md) | [11.3 d](/filings/0001437749-26-005907.md) | [11.9](/filings/0001437749-26-015588.md) | [7.0 d](/filings/0001437749-26-026267.md) | [8.4 d](/filings/0001437749-25-033626.md) | [22.4 d](/filings/0001437749-26-005907.md) | [59.8](/filings/0001437749-26-015588.md) | [50.5 d](/filings/0001437749-26-026267.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [181](/filings/0001437749-23-031307.md) | [183](/filings/0001437749-24-015724.md) | [183](/filings/0001437749-24-025596.md) | [182](/filings/0001437749-24-033984.md) | [181](/filings/0001437749-25-015552.md) | [183](/filings/0001437749-25-025492.md) | [204](/filings/0001437749-25-033626.md) | [225](/filings/0001437749-26-015588.md) | [229](/filings/0001437749-26-026267.md) | [233](/filings/0001437749-25-033626.md) | [226](/filings/0001437749-26-015588.md) | [221](/filings/0001437749-26-026267.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 211,565,426 at 2026-08-05, from the cover of the [10-Q filed 2026-08-06](/filings/0001437749-26-026267.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.